PMID- 29734388
OWN - NLM
STAT- MEDLINE
DCOM- 20180815
LR  - 20201214
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 5
DP  - 2018
TI  - A prospective evaluation of serum kynurenine metabolites and risk of pancreatic 
      cancer.
PG  - e0196465
LID - 10.1371/journal.pone.0196465 [doi]
LID - e0196465
AB  - BACKGROUND: Serum pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, is 
      associated with reduced risk of pancreatic cancer. Data on functional measures of 
      vitamin B6 status and risk of pancreatic cancer is lacking. METHODS: A nested 
      case-control study involving 187 incident cases of pancreatic cancer and 362 
      individually matched controls were conducted within two prospective cohorts to 
      evaluate the associations between kynurenine metabolites in pre-diagnostic serum 
      samples and risk of pancreatic cancer. RESULTS: Higher serum concentrations of 
      3-hydroxyanthranilic acid (HAA) and the HAA:3-hydroxykynurenine (HK) ratio (a 
      measure for in vivo functional status of PLP) were significantly associated with 
      reduced risk of pancreatic cancer. Compared with the lowest tertile, odds ratios 
      (95% confidence intervals) of pancreatic cancer for the highest tertile was 0.62 
      (0.39, 1.01) for HAA, and 0.59 (0.35-0.98) for the HAA:HK ratio, after adjustment 
      for potential confounders and serum PLP (both Ps for trend<0.05). The 
      kynurenine:tryptophan ratio or neopterin was not significantly associated with 
      pancreatic cancer risk. CONCLUSIONS: The inverse association between HAA or the 
      HAA:HK ratio and risk of pancreatic cancer supports the notion that functional 
      status of PLP may be a more important measure than circulating PLP alone for the 
      development of pancreatic cancer.
FAU - Huang, Joyce Y
AU  - Huang JY
AUID- ORCID: 0000-0002-7757-7559
AD  - Division of Cancer Control and Population Science, UPMC Hillman Cancer Center, 
      University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
AD  - Department of Epidemiology, Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
FAU - Butler, Lesley M
AU  - Butler LM
AD  - Division of Cancer Control and Population Science, UPMC Hillman Cancer Center, 
      University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
AD  - Department of Epidemiology, Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
FAU - Midttun, Oivind
AU  - Midttun O
AD  - Bevital A/S, Bergen, Norway.
FAU - Ulvik, Arve
AU  - Ulvik A
AD  - Department of Clinical Science, University of Bergen, Bergen, Norway.
FAU - Wang, Renwei
AU  - Wang R
AD  - Division of Cancer Control and Population Science, UPMC Hillman Cancer Center, 
      University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
FAU - Jin, Aizhen
AU  - Jin A
AD  - National Registry of Diseases Office, Health Promotion Board, Singapore, Republic 
      of Singapore.
FAU - Gao, Yu-Tang
AU  - Gao YT
AD  - Department of Epidemiology, Shanghai Cancer Institute/Shanghai Jiaotong 
      University, Shanghai, China.
FAU - Ueland, Per M
AU  - Ueland PM
AD  - Department of Clinical Science, University of Bergen, Bergen, Norway.
AD  - Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, 
      Norway.
FAU - Koh, Woon-Puay
AU  - Koh WP
AD  - Duke-NUS Graduate Medical School Singapore, Singapore, Republic of Singapore.
AD  - Saw Swee Hock School of Public Health, National University of Singapore, 
      Singapore, Republic of Singapore.
FAU - Yuan, Jian-Min
AU  - Yuan JM
AUID- ORCID: 0000-0002-4620-3108
AD  - Division of Cancer Control and Population Science, UPMC Hillman Cancer Center, 
      University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
AD  - Department of Epidemiology, Graduate School of Public Health, University of 
      Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
LA  - eng
GR  - R01 CA144034/CA/NCI NIH HHS/United States
GR  - UM1 CA182876/CA/NCI NIH HHS/United States
GR  - UM1 CA182876/NH/NIH HHS/United States
GR  - R01 CA144034/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20180507
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 1UQB1BT4OT (3-Hydroxyanthranilic Acid)
RN  - 27723548JL (3-hydroxykynurenine)
RN  - 343-65-7 (Kynurenine)
RN  - 5V5IOJ8338 (Pyridoxal Phosphate)
RN  - 8059-24-3 (Vitamin B 6)
SB  - IM
MH  - 3-Hydroxyanthranilic Acid/*analysis
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - China
MH  - Female
MH  - Humans
MH  - Kynurenine/*analogs & derivatives/analysis/blood/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Pancreatic Neoplasms/metabolism
MH  - Prospective Studies
MH  - Pyridoxal Phosphate/blood
MH  - Risk Factors
MH  - Vitamin B 6/blood
PMC - PMC5937773
COIS- Competing Interests: Bevital A/S performed laboratory assays for metabolites of 
      tryptophan and kyurenine in serum samples of all study subjects. This does not 
      alter our adherence to PLOS ONE policies on sharing data and materials.
EDAT- 2018/05/08 06:00
MHDA- 2018/08/16 06:00
PMCR- 2018/05/07
CRDT- 2018/05/08 06:00
PHST- 2017/05/09 00:00 [received]
PHST- 2018/04/15 00:00 [accepted]
PHST- 2018/05/08 06:00 [entrez]
PHST- 2018/05/08 06:00 [pubmed]
PHST- 2018/08/16 06:00 [medline]
PHST- 2018/05/07 00:00 [pmc-release]
AID - PONE-D-17-17929 [pii]
AID - 10.1371/journal.pone.0196465 [doi]
PST - epublish
SO  - PLoS One. 2018 May 7;13(5):e0196465. doi: 10.1371/journal.pone.0196465. 
      eCollection 2018.